Michael V Milburn
Overview
Explore the profile of Michael V Milburn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
3802
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eisner J, de Jong F, Shibata Y, Mayhew G, Davison J, Carcione J, et al.
Clin Cancer Res
. 2024 Sep;
30(23):5374-5384.
PMID: 39325014
Purpose: The Genomic Analysis of High-Risk Non-Muscle-Invasive Bladder Cancer (GARNER) study investigated FGFR alteration (ALT) frequency and the clinical outcome relationship with Bacillus Calmette-Guérin (BCG) treatment in high-risk non-muscle-invasive bladder...
2.
Beebe K, Eisner J, Guo J, Shibata Y, Davison J, Uronis J, et al.
J Immunol
. 2024 May;
213(1):29-39.
PMID: 38767437
High-dose (HD) IL-2 was the first immuno-oncology agent approved for treating advanced renal cell carcinoma and metastatic melanoma, but its use was limited because of substantial toxicities. Multiple next-generation IL-2...
3.
Eisner J, Mayhew G, Davison J, Beebe K, Shibata Y, Guo Y, et al.
Clin Cancer Res
. 2023 May;
29(16):3203-3213.
PMID: 37233991
Purpose: The Piedmont study is a prospectively designed retrospective evaluation of a new 48-gene antifolate response signature (AF-PRS) in patients with locally advanced/metastatic nonsquamous (NS) non-small cell lung cancer (NSCLC)...
4.
Eisner J, Beebe K, Mayhew G, Shibata Y, Guo Y, Farhangfar C, et al.
Cancer Res Commun
. 2023 Mar;
2(8):894-903.
PMID: 36923304
Significance: Next-generation IL2 agents, designed for improved tolerability over traditional HD-IL2 (aldesleukin), are in clinical development. Retrospective molecular tumor profiling of patients treated with HD-IL2 or anti-PD-1 therapy provides insights...
5.
Nag A, Kurushima Y, Bowyer R, Wells P, Weiss S, Pietzner M, et al.
Hum Mol Genet
. 2020 Jan;
29(5):864-875.
PMID: 31960908
Saliva, as a biofluid, is inexpensive and non-invasive to obtain, and provides a vital tool to investigate oral health and its interaction with systemic health conditions. There is growing interest...
6.
7.
Wu H, Bogdanov M, Zhang Y, Sun K, Zhao S, Song A, et al.
Sci Rep
. 2016 Jul;
6:29637.
PMID: 27436223
Although Lands' cycle was discovered in 1958, its function and cellular regulation in membrane homeostasis under physiological and pathological conditions remain largely unknown. Nonbiased high throughput metabolomic profiling revealed that...
8.
Miller M, Kennedy A, Eckhart A, Burrage L, Wulff J, Miller L, et al.
J Inherit Metab Dis
. 2016 May;
39(5):757.
PMID: 27225280
No abstract available.
9.
Guo L, Milburn M, Ryals J, Lonergan S, Mitchell M, Wulff J, et al.
Proc Natl Acad Sci U S A
. 2015 Aug;
112(35):E4901-10.
PMID: 26283345
Precision medicine, taking account of human individuality in genes, environment, and lifestyle for early disease diagnosis and individualized therapy, has shown great promise to transform medical care. Nontargeted metabolomics, with...
10.
Miller M, Kennedy A, Eckhart A, Burrage L, Wulff J, Miller L, et al.
J Inherit Metab Dis
. 2015 Apr;
38(6):1029-39.
PMID: 25875217
Global metabolic profiling currently achievable by untargeted mass spectrometry-based metabolomic platforms has great potential to advance our understanding of human disease states, including potential utility in the detection of novel...